Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

FUJIFILM Diosynth Biotechnologies Opens Dedicated State-Of-The-Art Cell Culture Process Development Laboratories in Wilton Centre

FUJIFILM Diosynth Biotechnologies
Posted on: 12 Sep 17

FUJIFILM Diosynth Biotechnologies, a leading Contract Development and Manufacturing Organization (CDMO) with experience focused on the development and manufacture of recombinant biopharmaceuticals and advanced therapies, has announced its opening of the 10,000 square foot, state-of-the-art cell culture Process Development Laboratories in Wilton Centre, Teesside. These laboratories were realized through a JPY1 billion ($9M USD) investment which is part of the greater JPY14 billion ($130M USD) expansion announced by FUJIFILM Corporation in April 2017. A grant from Let’s Grow, which is part of The Regional Growth Fund also contributed to the overall investment as part of FUJIFILM Diosynth Biotechnologies’ continued growth in the Tees Valley. The new facility will bring new sustainable, high tech jobs to the region.

This Smart News Release features an interactive multimedia capsule. View the full release here: http://www.businesswire.com/news/home/20170912006164/en/

Dedicated state-of-the-art cell culture Process Development Laboratories in Wilton, Teesside (Photo: Fujifilm)

A dedication ceremony was held on September 12, 2017. “Fujifilm’s investment in a new facility on Teesside demonstrates the strength of the UK’s life sciences sector and brings more highly-skilled jobs to the region,” said Lord Prior. “The UK has a very strong science and innovation base and through our Industrial Strategy we are ensuring we continue to be at the forefront of pioneering research and the destination of choice for inward investment.” Lord Prior of Brampton and Mr. Daisuke Matsunaga, Consul General of Japan in the U.K. addressed the audience of local government members and the biotech community during the event.

The new laboratories will be dedicated to support the Saturn™ mAb Platform cell culture Process Development activities. The Saturn mAb Platform™ is designed to enable rapid access to process development and manufacturing capacity.

“These laboratories are designed to incorporate the latest high-throughput technologies, including fully automated high throughput bioreactors and chromatography systems,” said Andy Topping, Chief Scientific Officer, FUJIFILM Diosynth Biotechnologies.

“The Saturn™ Process Development Laboratories are a huge differentiator in the cell culture and monoclonal antibody process development space,” said Paul Found, COO, FUJIFILM Diosynth Biotechnologies UK sites. “By dedicating these facilities and bringing new technologies we will be effectively supporting our customers in the rapid delivery of monoclonal antibody therapies to patients all over the world. This is part of our commitment as Partners for life in the advancement of medicines.”

About Fujifilm

FUJIFILM Diosynth Biotechnologies an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Billingham and Redcar, UK, RTP, North Carolina and College Station, Texas. FUJIFILM Diosynth has over twenty five years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™ cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation. For more information, go to: www.fujifilmdiosynth.com

FUJIFILM Holdings Corporation, Tokyo, Japan delivers innovative solutions across a broad range of businesses, derived from the depth of knowledge of core and fundamental technologies required for the complex design, engineering and manufacturing of photographic film. These business fields include medical digital radiography, women's health, endoscopy, ultrasound, medical informatics, CDMO biopharmaceuticals, regenerative medicine, pharmaceuticals and cosmetics. Other businesses include graphic systems, highly functional materials, optical devices, imaging, digital imaging and document products. In the year ended March 31, 2017, the company had global revenues of $20.7 billion, at an exchange rate of 112 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.

All product and company names herein may be trademarks of their registered owners.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170912006164/en/

Business Wire
www.businesswire.com

Last updated on: 12/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.